This module uses fundamental data of BioAffinity Technologies to approximate its Piotroski F score. BioAffinity Technologies F Score is determined by combining nine binary scores representing 3 distinct fundamental categories of bioAffinity Technologies Warrant. These three categories are profitability, efficiency, and funding. Some research analysts and sophisticated value traders use Piotroski F Score to find opportunities outside of the conventional market and financial statement analysis.They believe that some of the new information about BioAffinity Technologies financial position does not get reflected in the current market share price suggesting a possibility of arbitrage. Check out BioAffinity Technologies Altman Z Score, BioAffinity Technologies Correlation, BioAffinity Technologies Valuation, as well as analyze BioAffinity Technologies Alpha and Beta and BioAffinity Technologies Hype Analysis.
BioAffinity
Piotroski F Score
Enterprise Value
Ptb Ratio
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Capex To Depreciation
Pb Ratio
Free Cash Flow Per Share
Roic
Inventory Turnover
Net Income Per Share
Days Of Inventory On Hand
Payables Turnover
Cash Per Share
Pocfratio
Interest Coverage
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Graham Number
Shareholders Equity Per Share
Debt To Equity
Capex Per Share
Graham Net Net
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Short Term Coverage Ratios
Price Earnings Ratio
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Ebt Per Ebit
Effective Tax Rate
Company Equity Multiplier
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Cash Ratio
Days Of Inventory Outstanding
Cash Flow Coverage Ratios
Price To Book Ratio
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Return On Assets
Price Fair Value
Return On Equity
Change In Cash
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Other Cashflows From Financing Activities
Depreciation
Other Non Cash Items
Capital Expenditures
Total Cash From Operating Activities
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Investments
Stock Based Compensation
Total Assets
Short Long Term Debt Total
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Property Plant And Equipment Net
Net Debt
Retained Earnings
Accounts Payable
Cash
Non Current Assets Total
Non Currrent Assets Other
Cash And Short Term Investments
Liabilities And Stockholders Equity
Other Current Assets
Other Stockholder Equity
Total Liab
Total Current Assets
Short Term Debt
Common Stock
Non Current Liabilities Total
Inventory
Net Invested Capital
Short Long Term Debt
Capital Stock
Net Working Capital
Depreciation And Amortization
Interest Expense
Gross Profit
Other Operating Expenses
Operating Income
Ebit
Research Development
Ebitda
Cost Of Revenue
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Income Tax Expense
Tax Provision
Net Interest Income
Interest Income
Selling General Administrative
Total Revenue
Net Income From Continuing Ops
Reconciled Depreciation
Probability Of Bankruptcy
At this time, BioAffinity Technologies' Net Debt To EBITDA is fairly stable compared to the past year. Debt To Equity is likely to climb to 0.1 in 2024, despite the fact that Net Debt is likely to grow to (1.2 M). At this time, BioAffinity Technologies' Graham Number is fairly stable compared to the past year. Shareholders Equity Per Share is likely to climb to 0.58 in 2024, whereas Operating Cash Flow Per Share is likely to drop (0.72) in 2024.
At this time, it appears that BioAffinity Technologies' Piotroski F Score is Healthy. Although some professional money managers and academia have recently criticized Piotroski F-Score model, we still consider it an effective method of predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient long-term portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
BioAffinity Technologies Piotroski F Score Drivers
The critical factor to consider when applying the Piotroski F Score to BioAffinity Technologies is to make sure BioAffinity is not a subject of accounting manipulations and runs a healthy internal audit department. So, if BioAffinity Technologies' auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if BioAffinity Technologies' financial numbers are properly reported.
One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to project the various growth rates. Understanding the correlation between BioAffinity Technologies' different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards BioAffinity Technologies in a much-optimized way.
F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.
Book Value Per Share
0.58
At this time, BioAffinity Technologies' Book Value Per Share is fairly stable compared to the past year.
About BioAffinity Technologies Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze bioAffinity Technologies Warrant's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BioAffinity Technologies using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of bioAffinity Technologies Warrant based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When running BioAffinity Technologies' price analysis, check to measure BioAffinity Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioAffinity Technologies is operating at the current time. Most of BioAffinity Technologies' value examination focuses on studying past and present price action to predict the probability of BioAffinity Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioAffinity Technologies' price. Additionally, you may evaluate how the addition of BioAffinity Technologies to your portfolios can decrease your overall portfolio volatility.